ProAssurance (NYSE:PRA – Get Free Report) had its price objective boosted by research analysts at Truist Financial from $14.00 to $18.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “hold” rating on the insurance provider’s stock. Truist Financial’s target price points to a potential upside of 4.96% from the company’s current price.
A number of other research analysts also recently commented on PRA. StockNews.com upgraded ProAssurance from a “hold” rating to a “buy” rating in a report on Monday. JMP Securities decreased their price objective on ProAssurance from $22.00 to $20.00 and set a “market outperform” rating for the company in a research report on Wednesday, July 17th. Finally, Piper Sandler cut ProAssurance from an “overweight” rating to a “neutral” rating and set a $18.00 price target for the company. in a report on Monday. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.67.
Check Out Our Latest Analysis on PRA
ProAssurance Price Performance
Institutional Trading of ProAssurance
Institutional investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd bought a new position in shares of ProAssurance during the 2nd quarter worth approximately $28,000. nVerses Capital LLC purchased a new stake in ProAssurance in the 3rd quarter valued at $44,000. Innealta Capital LLC bought a new position in shares of ProAssurance during the 2nd quarter worth $69,000. ProShare Advisors LLC bought a new position in ProAssurance in the 1st quarter worth about $132,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of ProAssurance during the 2nd quarter valued at about $166,000. 85.58% of the stock is currently owned by institutional investors and hedge funds.
About ProAssurance
ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers’ Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.
Featured Stories
- Five stocks we like better than ProAssurance
- How to Start Investing in Real Estate
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- What is the S&P 500 and How It is Distinct from Other Indexes
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for ProAssurance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProAssurance and related companies with MarketBeat.com's FREE daily email newsletter.